Scientific Poster Presentations, II

Tuesday, October 15
Convention Center:
Fran Hill NE Exhibit Hall
8:00 a.m.–10:00 a.m.

ENCORE PRESENTATIONS
Abstracts marked with an “E” are Encore Presentations. Encore Presentations undergo the same peer-review process as all other presentations, but they may have been presented elsewhere or published in abstract form before the 2013 ACCP Annual Meeting. For presentations, the abstract title, authors, and original citation (if provided) are published.

AWARDS COMPETITION
Abstracts marked with an “F” listed on pages 157–160 are finalists for the Best Student Poster, Best Resident and Fellow Poster, and Best Paper awards. These papers were selected by a special panel of reviewers. The award winner for the Best Paper will be announced at 9:45 a.m. on Tuesday, October 15, in the Fran Hill NE Exhibit Hall.

ORIGINAL RESEARCH
These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

Adult Medicine
4. Evaluation of N-Acetylcysteine for the Prevention of Contrast-Induced Nephropathy. Sara K. Richter, Pharm.D.,1 Andrew J. Crannage, Pharm.D., BCPS; (1)Division of Pharmacy Practice, St. Louis College of Pharmacy/Mercy Hospital St. Louis, St. Louis, MO; (2)St. Louis College of Pharmacy, St. Louis, MO

Cardiovascular
18. Defining the Dose Response of Oral Sildenafil in Patients with Advanced Heart Failure. Douglas L. Jennings, Pharm.D., BCPS (AQ-CV),1 Andrew Arter, Pharm.D.,2 Jeffrey Morgan, M.D., David Lanfear, M.D.3; (1)Henry Ford Hospital, Detroit, MI; (2)Detroit Medical Center; (3)Henry Ford Hospital

19. The Use of Antiplatelet Agents in Secondary Prevention of Stroke: A Network Meta-analysis. Rhynn J. Malloy, Pharm.D.,1 Abir O. Kanaan, Pharm.D.,2 Matthew A. Silva, Pharm.D.,2 Jennifer L. Donovan, Pharm.D.2; (1)School of Pharmacy, MCPHS University, Worcester, MA; (2)MCPHS University, Worcester, MA

20E. Participation in a Multi-disciplinary Heart Failure Disease Management Program Minimizes Risk of Aldosterone Antagonist–Induced Hyperkalemia. Shawn Anderson, Pharm.D., BCACP, Kristyn Mulqueen, Pharm.D., BCPS; Department of Veterans Affairs, Gainesville, FL
21E. Effects of an Amlodipine- and Olmesartan Medoxomil–Based Titration Regimen in Patients with Hypertension, Type 2 Diabetes, and Metabolic Syndrome.
C. Venkata S. Ram, M.D., MACP, FACC, FASH,1 Richard A. Sachson, M.D., FACP, FACE,2 Chunlin Qian, Ph.D.,3 Kathy A. Stoakes, RN, BSN,3 Kathleen J. Chavanu, Pharm.D.3; (1)Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX; (2)Endocrine Associates of Dallas, Dallas, TX; (3)Daiichi Sankyo, Inc., Parsippany, NJ

22. The High-Dose Rosuvastatin Once-Weekly Study (HDROWS) – The Effects on Advanced Lipid, Glycemic, and Inflammatory Panels.
James M. Backes, Pharm.D.,1 Janelle F. Ruisinger, Pharm.D.,2 Cheryl Gibson, Ph.D.,3 Stephen Varvel, Ph.D.,4 Patrick M. Moriarty, M.D.5; (1)Mail Stop 4047, University of Kansas Atherosclerosis and LDL-Apheresis Center, Kansas City, KS; (2)University of Kansas School of Pharmacy Department of Pharmacy Practice, University of Kansas Atherosclerosis and LDL-Apheresis Center, Kansas City, KS; (3)Kansas University Medical Center, Kansas City, KS; (4)Health Diagnostics Lab Inc., Richmond, VA; (5)University of Kansas Atherosclerosis and LDL-Apheresis Center, Kansas City, KS

23E. Efficacy of an Amlodipine/Olmesartan Medoxomil Regimen in Patients Uncontrolled on Prior Diuretic Monotherapy.
Joel M. Neutel, M.D.,1 Alan Graff, M.D.,2 Jen-Fue Maa, Ph.D.,3 Ali Shojaee, Pharm.D.,3 Kathleen J. Chavanu, Pharm.D.3; (1)Orange County Research Center, Tustin, CA; (2)Private Practice, Fort Lauderdale, FL; (3)Daiichi Sankyo, Inc., Parsippany, NJ

24E. Outcomes with Ticagrelor versus Clopidogrel in Relation to High-Sensitivity Troponin-T in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with Early Invasive or Non-invasive Treatment – A Substudy from the Prospective Randomized PLAtelet Inhibition. Lars Wallentin, M.D., Ph.D.,1 Stefan James, M.D., Ph.D.,1 Evangelos Giannitsis, M.D.,2 Hugo Katus, M.D., Ph.D.,2 Richard C. Becker, M.D., Med.,3 Christopher P. Cannon, M.D.,4 Jay Horrow, M.D., M.S., FAHA,5 Steen Husted, M.D., DSc,6 Agneta Siegbahn, M.D., Ph.D., FESC,7 Gabriel P. Steg, M.D.,8 Robert F. Storey, M.D., Ph.D.,9 Lisa Wernroth, M.Sc.,7 Robert Harrington, M.D.,10; (1)Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University; (2)Department of Cardiology, University of Heidelberg; (3)Department of Cardiology, Duke Clinical Research Institute, Duke University Medical Center; (4)Cardiovascular Division, Brigham and Women’s Hospital; (5)Global Medicines Development, AstraZeneca, LP; (6) Department of Medicine, Hospital Unit West; (7)Uppsala Clinical Research Center, Uppsala University; (8)Département de Cardiologie, Université Paris Diderot; (9)Department of Cardiovascular Science, University of Sheffield; (10)Department of Medicine, Stanford University

Yvonne Phan, Pharm.D., BCPS,1 Toni Ripley, Pharm.D., FCCP, BCPS (AQ Cardiology),1 Holly Herring, Pharm.D., BCPS,1 Donald Harrison, Ph.D., FAPhA,2 R. Chris Rathbun, Pharm.D., BCPS3; (1)The University of Oklahoma College of Pharmacy, Oklahoma City, OK; (2)College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK; (3)Department of Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Tiffany Pon, Pharm.D., BCPS,1 William Dager, Pharm.D., BCPS (AQ Cardiology), FCCP, FCCM, FCSHP,4 A. Josh Roberts, Pharm.D., BCPS,1 Richard White, M.D.,2; (1)Department of Pharmacy, University of California, Davis Medical Center, Sacramento, CA; (2)Department of Internal Medicine, University of California, Davis Medical Center, Sacramento, CA
27. The Effect of GLP-1 Receptor Agonists on Targets for Cardiovascular Risk Reduction. 
Christopher Westrick, Pharm.D., Melissa Snider, Pharm.D., BCPS, CLS, Nicole Arradaza, M.S., 
Kavita Sharma, M.D., ABCL Diplomate; The Ohio State University Wexner Medical Center, 
Columbus, OH

28. Comparative Accuracy of Pharmacogenetic Warfarin Dosing Algorithms and the Warfarin 
Dosing Label Plus Clinical Judgment. 
Yana Labinov, Pharm.D.,¹ Robert DiDomenico, Pharm.D.,² Edith A. Nutescu, Pharm.D.,² 
Larisa H. Cavallari, Pharm.D.²; (1)University of Illinois at Chicago College of Pharmacy, Chicago, IL; 
(2)University of Illinois at Chicago College of Pharmacy, Chicago, IL

29. Anti-factor Xa Assay vs. aPTT for the Monitoring of Unfractionated Heparin Infusions in 
Patients Treated for Cardiac Indications. 
Matthew Marston Jr, Pharm.D.,¹ Emily Heath, Pharm.D., B.S., Renee Ford, Pharm.D., BCPS,¹ 
Lukas Griffin, B.S., Marybeth Boudreau, Pharm.D., BCPS²; (1)Eastern Maine Medical Center, 
Bangor, ME

30. Influence of Clinical and Genetic Characteristics on P2Y12 Inhibitor Selection in High-
Risk Patients with Coronary Artery Disease. 
Brent N. Reed, Pharm.D., BCPS,¹ Robert Wittorf, Pharm.D.,² David C. Plitt, M.D.,³ Karen E. 
Weck, M.D.,⁴ Craig R. Lee, Pharm.D., Ph.D., FCCP; George A. Stouffer, M.D.⁶; (1)Department 
of Pharmacy, University of North Carolina Health Care, Chapel Hill, NC; (2)Division of Phar-
macotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of 
North Carolina; (3)Division of Cardiology; School of Medicine, University of North Carolina; 
(4)Department of Pathology and Laboratory Medicine, School of Medicine, University of 
North Carolina; (5)Division of Pharmacotherapy and Experimental Therapeutics, Eshelman 
School of Pharmacy, University of North Carolina, Chapel Hill, NC; (6)Division of Cardiology; 
School of Medicine, University of North Carolina, Chapel Hill, NC

31E. Patient Outcomes with Anticoagulation Therapy After Hip and Knee Replacement: 
Comparison of Two Models of Care. 
Sacheeta Bathija, M.S.,¹ Surrey Walton, Ph.D.,¹ Denys Lau, Ph.D.,¹ William Galanter, M.D.,² 
Glen Schumock, Pharm.D., Ph.D.,¹ Edith Nutescu, Pharm.D.;¹ (1)University of Illinois at Chi-
cago College of Pharmacy, Department of Pharmacy Systems Outcomes and Policy; (2)Uni-
versity of Illinois at Chicago, Section of General Internal Medicine, Department of Medicine, 
Chicago, IL; (3)University of Illinois at Chicago College of Pharmacy, Department of Phar-
macy Practice, Chicago, IL

32F. Predictors of Medication Adherence: Results from the Atherosclerosis Risk in 
Communities Study. 
Jo E. Rodgers, Pharm.D., FCCP, BCPS (AQ Cardiology),¹ Carla A. Sueta, M.D., Ph.D.,² Anna 
Kucharska-Newton, Ph.D.,³ Sally Stearns, Ph.D.,⁴ Patricia Chang, M.D., MHS, FACC;⁵ Hanyu 
Ni, Ph.D.,⁶ Hadi Beyhaghi, M.D.,⁷ Emily M. Thudium, Pharm.D.,¹ Lei Zhou, M.D., M.D.,⁷ Elizabeth A. 
Blair, Pharm.D.,⁸ Jerome Federspiel, Ph.D.;¹ (1)Division of Pharmacotherapy and Experimental 
Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; 
(2)Division of Cardiology, School of Medicine, University of North Carolina, Chapel Hill, NC; 
(3)Epidemiology, UNC Gillings School of Public Health, Chapel Hill, NC; (4)Health Policy 
and Management, UNC Gillings School of Public Health, Chapel Hill, NC; (5)Department of 
Medicine, Division of Cardiology, University of North Carolina Health Care, Chapel Hill, NC; 
(6)Epidemiology, National Heart, Lung, and Blood Institute, Chapel Hill, NC; (7)UNC Gillings 
School of Public Health; (8)Division of Pharmacotherapy and Experimental Therapeutics, Es-
helman School of Pharmacy, University of North Carolina, Chapel Hill, NC
33E. The Effect of Cardiovascular-Credentialed Pharmacists on Process Measures and Outcomes in Myocardial Infarction and Heart Failure.

*Michael P. Dorsch, Pharm.D., M.S., BCPS (AQ-CV),*¹ Jennifer M. Lose, Pharm.D., BCPS,² Robert DiDomenico, Pharm.D.;¹ (1)University of Michigan Hospitals and Health Centers, Ann Arbor, MI; (2)Mayo Clinic, Rochester, MN; (3)University of Illinois at Chicago College of Pharmacy, Chicago, IL

**Community Pharmacy Practice**

34. Availability and Needs of Herbal Medicinal Information Resources at Community Pharmacy, Riyadh Region, Saudi Arabia.

*Mohamed Alarifi, Ph.D.;* Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

**Education/Training**

41. Implementing and Assessing an Elective Learning Experience in Medical Missions for PGY1 Pharmacy Residents.

*Elias Chahine, Pharm.D., BCPS (AQ-ID),*¹ Mara Poulakos, Pharm.D.,² Jamie Fairclough, MS-Pharm, Ph.D., MPH,² Angela Skaff, Student Pharmacist,² Riley Williams II, Pharm.D.;² (1)Palm Beach Atlantic University, Lloyd L. Gregory School of Pharmacy, West Palm Beach, FL; (2)Palm Beach Atlantic University, Lloyd L. Gregory School of Pharmacy, West Palm Beach, FL

42. Development of Criteria for Clinical Activities for Pharmacy Practice Faculty at Annual Evaluations.

*April N. Smith, Pharm.D., BCPS, Pamela A. Foral, Pharm.D., BCPS, Jon T. Knezevich, Pharm.D., BCPS, Michael S. Monaghan, Pharm.D., BCPS;* Creighton University School of Pharmacy and Health Professions, Omaha, NE

43. Improvement in Pharmacy Students’ Attitudes Toward Mental Illness as the Result of Participation in an Elective Course Based on Mental Illness and Treatment in the Movies.

*Marshall E. Cates, Pharm.D., FASHP, BCPP,*¹ Kristina Mullins, Pharm.D. Candidate,¹ Thomas Woolley, Ph.D.;¹ (1)Samford University McWhorter School of Pharmacy, Birmingham, AL; (2)Samford University, Birmingham, AL

44. Does Participation in Actual Drug Testing Influence the Attitudes of First-Year Pharmacy Students Toward Mandatory Drug Testing?

*Marshall E. Cates, Pharm.D., FASHP, BCPP,*¹ Michael Hogue, Pharm.D., FAPhA, FNAP;¹ Thomas Woolley, Ph.D.;¹ (1)Samford University McWhorter School of Pharmacy, Birmingham, AL; (2)Samford University, Birmingham, AL

45. Doctor of Pharmacy Students’ Perception of Telemedicine Prior to and Following Completion of a Telemedicine Course.

*Juliana Chan, Pharm.D., Phuong Dao, Pharm.D. Candidate, Zahra Kassamali, Pharm.D., Melissa E. Badowski, Pharm.D.;* University of Illinois at Chicago College of Pharmacy, Chicago, IL

46. Pharmacy Students’ Competency with Medication Delivery Devices.

*Shandrika Williams, Pharm.D., BCACP, CDE,*¹ Margarita Echeverri, Ph.D., M.Sc.;¹ (1)College of Pharmacy – DCAS, Xavier University of Louisiana College of Pharmacy, New Orleans, LA; (2)Xavier University of Louisiana, College of Pharmacy, New Orleans, LA

47. Decision-making Style Preference Among Third-Year Pharmacy Students.

*Greene Shepherd, Pharm.D., Wendy Cox, Pharm.D., Charlene Williams, Pharm.D., Jacqueline McLaughlin, Ph.D.;* Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy
48. Pilot of Interprofessional Education Using High-fidelity Simulation. Frank M. Szczerba, Pharm.D., Michael J. Peeters, Pharm.D., MEd, BCPS, Paul Rega, M.D., FA-CEP; (1)University of Toledo Medical Center, Toledo, OH; (2)University of Toledo College of Pharmacy, Toledo, OH; (3)University of Toledo College of Medicine, Toledo, OH

49. Evaluation of the Ambulatory Care Practice and Research Network Mentoring Program. Kelly A. Lempicki, Pharm.D., BCPS, Melody L. Hartler, Pharm.D., AE-C, Marissa C. Salvo, Pharm.D.; (1)Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, IL; (2)Cedarville University School of Pharmacy, Cedarville, OH; (3)University of Connecticut – School of Pharmacy, Storrs, CT

50. Evaluation of the Impact of Instruction and Feedback on Reflective Responses Completed by Fourth-Year Pharmacy Students on Their Ambulatory Care Advanced Pharmacy Practice Experience. Robyn Teply, Pharm.D., Mikayla Spangler, Pharm.D., Laura Klug, Pharm.D., Jennifer Tilleman, Pharm.D., Kelli Coover, Pharm.D.; Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE

51. Describing Pharmacy Residents’ Cognitive Abilities. Michael J. Peeters, Pharm.D., MEd, BCPS, Julie A. Murphy, Pharm.D., FCCP, FASHP, BCPS; University of Toledo College of Pharmacy, Toledo, OH

52E. Pediatric Education Diagnosis Survey (PEDS): Analyzing Pediatric Education Within Pharm.D. Programs in the United States. Phillip Weddle, Pharm.D., Terri Warholak, Ph.D., Hanna Phan, Pharm.D.; Department of Pharmacy Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ

53. Evaluation of Focused Teaching During Advanced Pharmacy Practice Experiences. Andrew J. Crannage, Pharm.D., BCPS, Jamie M. Pitlick, Pharm.D., BCPS, Amy M. Drew, Pharm.D., BCPS, Lindsay M. Rippelmeyer, Pharm.D., Julie A. Murphy, Pharm.D., FCCP, FASHP, BCPS; (1)St. Louis College of Pharmacy, St. Louis, MO; (2)University of Toledo College of Pharmacy, Toledo, OH

54. American College of Clinical Pharmacy Student Chapters Survey 2013 Update. Andrew Smith, Pharm.D., BCPS (AQ-CV), Sandra Benavides, Pharm.D., Laura Tsu, Pharm.D., BCPS, Nancy Yunker, Pharm.D., BCPS; (1)UMKC School of Pharmacy, Kansas City, MO; (2)Nova Southeastern University, College of Pharmacy, Davie, FL; (3)Midwestern University – College of Pharmacy – Glendale, Glendale, AZ; (4)Virginia Commonwealth University School of Pharmacy, Richmond, VA

55E. Incorporating Multiple Mini Interviews in a Postgraduate Year One Pharmacy Residency Program Selection Process. Douglas Oyler, Pharm.D.; Department of Pharmacy, University of Kentucky, Lexington, KY

56. Simulation Training Improves Pharmacists’ Competency in Advanced Cardiac Life Support Response. Elizabeth VanWert, Pharm.D., Rose Sohraby, Pharm.D., Julie A. McIndoo, Pharm.D., Stephanie Younts, Pharm.D., BCPS, Conrado Gamboa, B.S., Darrel W. Hughes, Pharm.D., BCPS; Department of Pharmacy Services, University Health System, San Antonio, TX

58. Online vs. Live Lecture in an Evidence-Based Medicine Course: Effectiveness and Student Perception. Jennifer Phillips, Pharm.D., BCPS, Sean Mirk, Pharm.D., Huzefa Master, Pharm.D., BCPS; Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, IL
59. Clinical Pharmacotherapy Notes: Assessment of Students’ Perceptions and Performance.  
*Angela O. Shogbon, Pharm.D., BCPS*, Lisa M. Lundquist, Pharm.D., BCPS, Kathryn M. Momary, Pharm.D., BCPS; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA

60. Student Pharmacist’s Self-Assessment of Their Communication Skills with Health Care Providers.  
Lisa M. Lundquist, Pharm.D., BCPS, *Angela O. Shogbon, Pharm.D., BCPS*, Kathryn M. Momary, Pharm.D., BCPS; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA

61. Pharmacy Student Participation in an Interprofessional Medical Relief Trip as Members of a Joint Student Organization.  
*Jordan Masse, Pharm.D. Candidate 2014,*¹ Sabrina Grandi, Pharm.D. Candidate 2014,¹ Chih Chuang, M.D.,² Helen Berlie, Pharm.D., CDE¹; (1)Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI; (2)School of Medicine, Wayne State University, Detroit, MI

62. Pharmacy Student Perceptions and Performance After Using a Reverse Classroom Instructional Strategy in an Ambulatory Care Elective.  
*Stacey Thacker, Pharm.D., BCPS*, Jennifer L. Rosselli, Pharm.D.; Southern Illinois University Edwardsville School of Pharmacy, Edwardsville, IL

63. Evaluation of Scholarship and Research Among Full-time Pharmacy Practice Faculty Members Serving as Pharmacy Residency Preceptors.  
*Sarah A. Treadway, Pharm.D., BCPS,*¹ Shaunta’ Ray, Pharm.D., BCPS,² Debbie C. Byrd, Pharm.D., BCPS³; (1)Auburn University Harrison School of Pharmacy, Mobile, AL; (2)University of Tennessee College of Pharmacy, Knoxville, TN; (3)University of Tennessee Health Science Center, College of Pharmacy, Knoxville, TN

64. Student Pharmacists’ Reflections on the Challenges of Communicating Medication Therapy Recommendations to Physicians.  
*Paul Denvir, Ph.D.,¹ Jeffrey Brewer, Pharm.D., BCACP²; (1)Department of Humanities and Communication, Albany College of Pharmacy and Health Sciences, Albany, NY; (2)Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY

**Emergency Medicine**

65E. Propofol versus Benzodiazepine Infusion for Alcohol Withdrawal Requiring Mechanical Ventilation: A Retrospective Chart Review.  
Rose Sohraby, Pharm.D.,¹ Rebecca Attridge, Pharm.D., M.S., BCPS,² *Darrel W. Hughes, Pharm.D., BCPS*²; (1)Department of Pharmacy Services, University Health System, San Antonio, TX; (2)University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX

66. Is Low-Dose 3-Factor PCC Effective for Warfarin Reversal?  
*Jennifer Mai, Pharm.D., BCPS*, Harminder Sikand, Pharm.D., FCSHP, FASHP; Scripps Mercy Hospital, San Diego, CA

*Elizabeth VanWert, Pharm.D., Darrel W. Hughes, Pharm.D., BCPS; Department of Pharmacy Services, University Health System, San Antonio, TX
Gastroenterology

80. The Effect of Bariatric Surgery on Hypertension.  
*Sheila Wilhelm, Pharm.D., BCPS,¹ Jamie Young, Pharm.D. Candidate,² Pramodini Kale-Pradhan, Pharm.D.³; (1)Pharmacy Practice, Wayne State University and Harper University Hospital, Detroit, MI; (2)Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences; (3)Pharmacy Practice, Wayne State University and St. John Hospital and Medical Center, Detroit, MI

Geriatrics

82. Evaluation of Fall Risk Assessments in Community-Dwelling Veterans.  
*Mallory Jones, Pharm.D., Stephen Neu, Pharm.D.; Pharmacy Department, VA Tennessee Valley Healthcare System, Nashville, TN

85. Impact of Updated Beer’s Criteria on Percentage of Inappropriate Medication Use in a Long-term Care Facility.  
*Amber N. McLendon, Pharm.D.,¹ Amity Bunkofske, Pharm.D.,² C. Brock Woodis, Pharm.D.³; (1) Department of Pharmacy Practice, Campbell University College of Pharmacy & Health Sciences and Glenaire, Inc. CCRC, Buies Creek, NC; (2)Campbell University College of Pharmacy & Health Sciences, Buies Creek, NC; (3)Campbell University College of Pharmacy & Health Sciences, Buies Creek, NC; and Duke University Department of Community and Family Medicine, Durham, NC

Infectious Diseases

104. β-Lactam/β-lactamase Inhibitors versus Carbapenems for the Treatment of Urinary Tract Infections Caused by Extended-Spectrum β-lactamase–Producing Bacteria: A Retrospective Cohort Study.  
*Wei Xiang Tong, BS(Pharm), National University Singapore; Department of Pharmacy, Changi General Hospital, Singapore

105. Effects of Early Switching from Intravenous to Oral Antibiotics on the Outcomes of Patients with Bacteremia Secondary to Urinary Tract Infections.  
*Wei Xiang Tong, BS(Pharm), National University Singapore; Department of Pharmacy, Changi General Hospital, Singapore

106E. Antibiotic Exposure Among Heart Failure and Pneumonia Dual Diagnosis Patients: A Descriptive Analysis.  
*Mary Vacha, Pharm.D.,¹ Stacey Friedman, Pharm.D.,² Ryan Dull, Pharm.D.,³ Dave Schmidt, Pharm.D.¹; (1)Alegent Creighton Health, Omaha, NE; (2)Creighton University School of Pharmacy and Health Professions, Omaha, NE; (3)Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE

*Dipen A. Patel, Ph.D.,¹ Andrew F. Shorr, M.D.,² Jean Chastre, M.D.³ Michael Niederman, M.D.,⁴ Andrew Simor, M.D.,⁵ Jennifer M. Stephens, Pharm.D.,¹ Gaurang Bhatt, MSIA,⁶ Claudie Charbonneau, Ph.D.⁷ Xin Gao, Ph.D.,¹ Dilip Nathwani, M.D.⁸; (1)Pharmerit International, Bethesda, MD; (2)Washington Hospital Center, Washington, DC; (3)Pitié-Salpêtrière Hospital, Paris, France; (4)Winthrop-University Hospital, Mineola, NY; (5)Sunnybrook Health Sciences Centre, Toronto, ON, Canada; (6)Formerly of Pfizer, Inc., Collegeville, PA; (7)Pfizer P.I.O., Paris, France; (8)Ninewells Hospital & Medical School, Dundee, United Kingdom
*Linda Spooner, Pharm.D., BCPS,*¹ George Abraham, M.D., MPH;² (1)School of Pharmacy-Worcester/Manchester, Massachusetts College of Pharmacy and Health Sciences University, Worcester, MA; (2)Saint Vincent Hospital, Worcester, MA

109. Vancomycin Treatment Failures for MRSA Bacteremia Based on MIC. 
*Nicholas Mariani, Pharm.D. Candidate,*¹ Pramodini Kale-Pradhan, Pharm.D.,² Sheila Wilhelm, Pharm.D., BCPS;³ Shannon Jacobs, Pharm.D. Candidate;⁴ Leonard Johnson, M.D.;⁴ (1)Wayne State University, Detroit, MI; (2)Pharmacy Practice, Wayne State University and St. John Hospital and Medical Center, Detroit, MI; (3)Pharmacy Practice, Wayne State University and Harper University Hospital, Detroit, MI; (4)Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI; (5)St. John Hospital and Medical Center and Wayne State University, Detroit

110. Efficacy of Vancomycin Loading Doses in Patients with Severe Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infections. 
Leah Quealy, Pharm.D.,¹ *Dustin Waters, Pharm.D., BCPS,*² (1)Intermountain Healthcare – McKay-Dee Hospital Center, Ogden, UT; (2)Department of Pharmacy, Intermountain Healthcare – McKay-Dee Hospital Center, Ogden, UT

111E. Activity of Vancomycin and Piperacillin-Tazobactam in Combination Against Methicillin-Resistant *Staphylococcus aureus* and VAN-Intermediate *Staphylococcus aureus* in an *In Vitro* Pharmacokinetic/Pharmacodynamic Infection Model. 
Tom Dilworth, Pharm.D.;¹ Steve Leonard, Pharm.D.;² *Renee Mercier, Pharm.D.*³; (1)College of Pharmacy, University of New Mexico, Albuquerque, NM; (2)Northeastern University School of Pharmacy, Boston, MA; (3)University of New Mexico, Albuquerque, NM

112E. Characteristics and Cultures of Patients with Health Care–Associated Pneumonia (HCAP). 
*Kimberly Toussaint, Pharm.D.*¹ Jason Gallagher, Pharm.D.;² Peter Axelrod, M.D.;³ Kiran Parmatmuni, M.D.;³ (1)School of Pharmacy, Temple University School of Pharmacy, Philadelphia, PA; (2)Temple University School of Pharmacy, Philadelphia, PA; (3)Temple University Hospital

113E. Effect of Linezolid on Methicillin-Resistant *Staphylococcus aureus* (MRSA) Panton-Valentine Leukocidin (PVL) Production Utilizing an Enzyme-Linked Immunosorbent Assay. 
*Monique Dodd, MLS(ASCP)CM, Pharm.D. Candidate 2014,*¹ Julie Acosta, Pharm.D. Candidate 2017;² *Renee Mercier, Pharm.D.*³; (1)College of Pharmacy, University of New Mexico, Albuquerque, NM; (2)University of New Mexico, Albuquerque, NM

114. In Vivo Evaluation of Cardiac Toxicity with Caspofungin. 
*Kayla R. Stover, Pharm.D., BCPS,*¹ John D. Cleary, Pharm.D.;² (1)School of Pharmacy, University of Mississippi School of Pharmacy, Jackson, MS; (2)University of Mississippi Medical Center, Jackson, MS

*Luigi Brunetti, Pharm.D.*¹ Shirin Poustchi, Pharm.D. Candidate;¹ Julie Kalabalik, Pharm.D.;¹ Daniel Cunningham, M.D.;² Ronald Nahass, M.D.;² (1)Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ; (2)Somerset Medical Center, Somerville, NJ; (3)ID CARE, Hillsborough, NJ

116. Value of Methicillin-Resistant *Staphylococcus aureus* (MRSA) and Carbapenemase-Producing Enterobacteriaceae (CPE) Surveillance in Predicting Subsequent Infections. 
*Tae Park, Pharm.D.,¹ Amy Asheroff, B.A.,² Roopali Sharma, Pharm.D., B.S., BCPS, AAHIVP;¹ Michael Augenbraun, M.D.;¹ (1)SUNY Downstate Medical Center, Brooklyn, NY; (2)CUNY Hunter College, New York, NY
117. Comparison of In Vitro Susceptibilities of Extended-Spectrum β-Lactamase (ESBL)-Producing *Escherichia coli* to Imipenem and Ertapenem in a Four-Hospital Health System. 
*Robert Bush, Pharm.D.*, Eva Sullivan, Pharm.D., Harminder Sikand, Pharm.D., FCSHP, FASHP; Scripps Mercy Hospital, San Diego, CA

118E. Thickened Cell Wall as a Mechanism for Increased Telavancin Minimum Inhibitory Concentration in Methicillin-Resistant *Staphylococcus aureus*. 
*Keenan Ryan, Pharm.D. Candidate,¹ Renee Mercier, Pharm.D.,² Stephen Jett, Ph.D.³; (1)College of Pharmacy, University of New Mexico, Albuquerque, NM; (2)University of New Mexico, Albuquerque, NM; (3)University of New Mexico

119E. Clinical Utility of Rectal Swabs as a Predictor of Vancomycin-Resistant Enterococcal Infections Requiring Antibiotic Treatment. 
*Niyati Vakil, Pharm.D.,¹ Alexander Levine, Pharm.D.,¹ Hsin Lin, Pharm.D.,¹ Kelly Newman, Pharm.D.,¹ Christopher Lyman, Pharm.D.,¹ Daniel Yeh, M.D.,² David Hooper, M.D.,³ Christy Varughese, Pharm.D.¹; (1)Department of Pharmacy, Massachusetts General Hospital, Boston, MA; (2)Department of Surgery, Massachusetts General Hospital, Boston, MA; (3)Department of Infectious Diseases, Massachusetts General Hospital, Boston, MA

120. Population Pharmacokinetic Analysis of Ceftolozane/Tazobactam in Healthy Volunteers and Patients. 
*Gurudatt Chandorkar, Ph.D.,¹ Samer Mouksassi, Pharm.D., Ph.D.,² Ellie Hershberger, Pharm.D.,³ Gopal Krishna, Ph.D.³; (1)Clinical Pharmacology, Cubist Pharmaceuticals, Lexington, MA; (2)Pharsight Corp., Montreal, QC, Canada; (3)Cubist Pharmaceuticals, Lexington, MA

121E. Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis: A 10-Year Retrospective Analysis from a Tertiary Care, Academic Medical Center. 
*Tom Dilworth, Pharm.D.,¹ Jora Sliwinski, Pharm.D.,² Renee Mercier, Pharm.D.³; (1)College of Pharmacy, University of New Mexico, Albuquerque, NM; (2)Idaho State University, Pocatello, ID; (3)University of New Mexico, Albuquerque, NM

122E. High-throughput Screening Identifies Novel Compounds with Antifungal Activity Alone or in Combination with Fluconazole Against a Highly Resistant Clinical Isolate of *Candida albicans*. 
*Sarah G. Whaley, Pharm.D.,¹ Elizabeth Berkow, M.S.,¹ Marcus Maddox, B.S.,² Richard E. Lee, Ph.D.,² P. David Rogers, Pharm.D., Ph.D.¹; (1)University of Tennessee College of Pharmacy, Memphis, TN; (2)St. Jude Children’s Research Hospital, Memphis, TN

*Zhe Han, Pharm.D., Natasha N. Pettit, Pharm.D., Benjamin D. Brielmaier, Pharm.D.; University of Chicago Medicine, Chicago, IL

125. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese Patients. 
*Eun Kyoung Chung, Pharm.D.,¹ S. Christian Cheatham, Pharm.D.,² Megan R. Fleming, Pharm.D.,³ Michael B. Kays, Pharm.D.³; (1)Department of Pharmacy Practice, Purdue University College of Pharmacy, Indianapolis, IN; (2)Department of Pharmacy, Franciscan St. Francis Health – Indianapolis, Indianapolis, IN; (3)Methodist Dallas Medical Center, Dallas, TX

126. Association Between Vancomycin Minimum Inhibitory Concentrations and Patient Outcomes in Coagulase-Negative *Staphylococci* Bacteremia. 
*Christopher B. Adams, Pharm.D.,¹ David T. Bearden, Pharm.D.,² Miriam R. Elman, MPH,² Vivian Tang, Pharm.D Candidate 2014,² Jessina C. McGregor, Ph.D.³; (1)Department of Pharmacy Services, Oregon Health & Science University, Portland, OR; (2)College of Pharmacy, Oregon State University, Portland, OR; (3)Oregon State University/Oregon Health Science University, College of Pharmacy, Portland, OR
**Medication Safety**

127. Evaluation of the Impact of a Pharmacy-Driven Protocol on Argatroban Use. Kathryn L. Krei, Pharm.D.,1 Andrew J. Crannage, Pharm.D., BCPS,2 Joy R. Abu-Shanab, Pharm.D., BCPS2; (1)St. Louis College of Pharmacy/Mercy Hospital St. Louis, St. Louis, MO; (2)St. Louis College of Pharmacy, St. Louis, MO; (3)Mercy Hospital St. Louis, St. Louis, MO

**Nutrition**

133E. Improved Safety with Early De-Escalation of Intravenous Insulin Therapy for Critically Ill Patients with Renal Failure. Roland Dickerson, Pharm.D.,1 Allison Lynch, Pharm.D.,2 George Maish III, M.D.,1 Martin Croce, M.D.,1 Gayle Minard, M.D.,1 Rex Brown, Pharm.D.; (1)University of Tennessee Health Science Center, Memphis, TN; (2)Duke University Health System, Durham, NC

**Other**

134E. Institutional Review Board Barriers and Solutions Encountered in the Collaboration Among Pharmacists and Physicians to Improve Outcomes Now Study: A National Multi-center Practice-Based Implementation Trial. Eric MacLaughlin, Pharm.D.,1 Gail Ardery, Ph.D., RN,2 Eric Jackson, Pharm.D.,3 Timothy J. Ives, Pharm.D., MPH,4 Rodney B. Young, M.D.,5 David S. Fike, Ph.D.,6 Barry Carter, Pharm.D.; (1)Department of Pharmacy Practice, Texas Tech University Health Sciences Center, Amarillo, TX; (2)University of Iowa College of Pharmacy, Iowa City, IA; (3)University of Connecticut School of Medicine, Farmington, CT; (4)University of North Carolina, Eshelman School of Pharmacy, Chapel Hill, NC; (5)Texas Tech University Health Sciences Center School of Medicine, Amarillo, TX; (6)University of the Incarnate Word, San Antonio, TX

136. Reversal of Anticoagulation in Patients Presenting with an Acute Head Injury. Jennifer Petrie, Pharm.D.; School of Pharmacy, University of Wyoming, Laramie, WY

**Pediatrics**

147. Pediatric Assessment of Vancomycin Empiric Dosing. Daniel Rainkie, BSc(Pharm),1 Mary H.H. Ensom, Pharm.D., FCCP, FASHP, FCSHP, FCAHS;2 Roxane R. Carr, Pharm.D., FCSHP, BCPS, ACP;1 Children’s & Women’s Health Centre of British Columbia, Vancouver, BC, Canada; (2)The University of British Columbia, Children’s & Women’s Health Centre of British Columbia, Vancouver, BC, Canada; (3)Children’s & Women’s Health Centre of British Columbia, The University of British Columbia, Vancouver, BC, Canada

**Pharmacoepidemiology**

158. Adverse Drug Events Among Older Adults Discharged from Skilled Nursing Facilities to Home. Abir O. Kanaan, Pharm.D.,1 Jennifer L. Donovan, Pharm.D.,1 Terry S. Field, DSc,2 Jessica Ogarnek, M.S.,2 Peggy Preusse, RN,2 Devi Sundaresan, M.S.,2 Shawn Gagne, B.A.,2 Lawrence Garber, M.D.,2 Jennifer Tjia, M.D., MSCE,2 Sarah L. Cutrona, M.D., MPH,2 Jerry H. Gurwitz, M.D.;2 (1)MCPHS University, Worcester, MA; (2)Meyers Primary Care Institute, a joint endeavor of the University of Massachusetts Medical School, Reliant Medical Group, and Fallon Community Health Plan, Worcester, MA

159. Impact of FDA Warnings on Long-acting β-Agonist Use in a State Medicaid Program. Daniel Hartung, Pharm.D., MPH; College of Pharmacy, Oregon State University, Portland, OR
160. Association Between Hydromorphone Adverse Reactions and Obstructive Sleep Apnea (OSA): A Case-Control Study. 
*Jeffrey Reitz, Pharm.D., MPH,¹ Stephanie Wasserman, B.Sc.²; (1)Value Institute and Department of Pharmacy Services, Christiana Care Health System, Newark, DE; (2)Department of Pharmacy Services, Christiana Care Health System, Newark, DE

161F. Azithromycin-Associated Risk of Cardiovascular Death from Arrhythmia: A Review of the FDA Adverse Event Reporting System Database. 
*Tina Khadem, Pharm.D.,¹ Robbert Van Manen, M.S.,² Jack Brown, Pharm.D., M.S.³; (1)University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY; (2)Oracle Health Sciences Global Business Unit, Netherlands; (3)Strong Hospital, University of Rochester Medical Center, NY

162. Impact of Pharmacist-Administered Seasonal Influenza Vaccinations on Influenza Vaccination Coverage Rates for Adults in New York State. 
*Tina Khadem, Pharm.D.,¹ Jack Brown, Pharm.D., M.S.²; (1)University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY; (2)Strong Hospital, University of Rochester Medical Center, NY

Pharmacogenomics/Pharmacogenetics

*Julie H. Oestreich, Pharm.D., Ph.D.,¹ Lyle G. Best, M.D.,² Brody W. Crowe, Pharm.D. Candidate,³ Paul P. Dobesh, Pharm.D., FCCP, BCPS⁴; (1)Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha, NE; (2)Turtle Mountain Community College; (3)University of Nebraska Medical Center; (4)University of Nebraska Medical Center, Omaha, NE

164. A Prospective Evaluation to Determine an Association Between Genetic Mutations on Genes VDR, CYP2R1, DHCPR7, and GC with Vitamin D Deficiency Status. 
*Nicole Slater, Pharm.D.; Pharmacy Practice, Shenandoah University, Bernard J. Dunn School of Pharmacy, Winchester, VA

165. The Effect of SCN1A, SCN2A, ABCC2, and UGT2B7 Genetic Polymorphisms on Oxcarbazepine Dose Requirements in Chinese Han Patients with Epilepsy. 
*Chun-Lai Ma, Ph.D.,¹ Xun-Yi Wu, M.D.,² Zheng Jiao, Ph.D., Ming-Kang Zhong, Ph.D.; (1)Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China; (2)Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China

166. Impact of CYP2D6 Polymorphisms on the Clinical Response and Tolerability of Immediate-Release Metoprolol. 
*Issam Hamadeh, Pharm.D.,¹ Taimour Y. Langae, Ph.D., Yan Gong, Ph.D., Ben M. Burkley, M.S., Todd C. Skaar, Ph.D., Julie Johnson, Pharm.D., FCCP, FAHA, BCPS⁵; (1)Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL; (2)UF Health Personalized Medicine Program; Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics; University of Florida, Gainesville, FL

Psychiatry

175. A Pilot Study on Clozapine-Induced Blood Dyscrasias Among Singaporean Inpatient Clozapine Users. 
*Celine Tan, Pharm.D.,¹ Boon Tat Ng, M(Clin Pharm),² Pei Shi Ong, Ph.D.³; (1)Department of Pharmacy, Institute of Mental Health, Singapore; (2)Institute of Mental Health, Singapore; (3)National University of Singapore, Department of Pharmacy, Singapore
Alina Kuo, Pharm.D., BCPS,1 Bruce Capehart, M.D., MBA,2 Carol Smith Hammond, Ph.D.,2 Karen Tucker, Ph.D.,2 Artin Armagan, Ph.D.,3 Jamie Brown, Pharm.D., BCPS,4; (1)Inova Fairfax Hospital, Falls Church, VA; (2)Duke University Medical Center; (3)Duke University Medical Center; (4)Pharmacy Service, Durham VA Medical Center, Durham, NC

177. Evaluation of a Pharmacy-Provided Education on Measurement of Testosterone Levels in Older Males with Depression.
Danielle Hebel, Pharm.D.,1 Jamie M. Pitlick, Pharm.D., BCPS,2 Amy M. Drew, Pharm.D., BCPS; (1)St. Louis College of Pharmacy; (2)St. Louis College of Pharmacy, St. Louis, MO

Substance Abuse/Toxicology

181. Addiction to the Synthetic Cannabinoid Analog AM-2201.
S. Casey Laizure, Pharm.D.; University of Tennessee Department of Clinical Pharmacy, Memphis, TN

Transplantation/Immunology

Kimi Ueda, Pharm.D.,1 Anne Wiland, Pharm.D., BCPS,2 Kevin McCague, M.A.,2 V. Ram Peddi, M.D.;1 (1)Department of Transplantation, California Pacific Medical Center, San Francisco, CA; (2)Novartis Pharmaceuticals Corp., East Hanover, NJ; (3)California Pacific Medical Center, San Francisco, CA

183E. Adherence to Immunosuppressive Therapy to 4 Years After Kidney Transplantation: Prospective Data from the Observational Mycophenolic Acid Observational REnal Transplant (MORE) Study.
Demetra Tsapepas, Pharm.D., BCPS,1 Anthony Langone, M.D.,2 Laurence Chan, M.D.,3 Anne Wiland, Pharm.D.,4 Kevin McCague, M.A.,4 Marie Chisholm-Burns, Pharm.D.;1 (1)NY-Presbyterian Hospital-Columbia University Medical Center, New York, NY; (2)Vanderbilt University Medical Center, Nashville, TN; (3)University of Colorado School of Medicine, Aurora, CO; (4)Novartis Pharmaceuticals Corp., East Hanover, NJ; (5)University of Tennessee Health Science Center, TN

184E. Everolimus (EVR)-Facilitated Reduction of Tacrolimus (TAC) in De Novo Liver Transplant Recipients (LTxR): 12-24 Month Data from North America (NA).
W.C. Chapman, M.D., FACS,1 R.S. Brown Jr, M.D., MPH,2 D. Sudan, M.D.,3 K.D. Chavin, M.D., Ph.D.,4 B. Koneru, M.D.,5 M.A. Huang, M.D., M.S.,6 G. Junge, M.D., M.B.A.,7 J.M. Hexham, Ph.D., M.Sc.,8 G. Dong, Ph.D.,8 A. Wiland, Pharm.D., BCPS,8 D. Patel, M.D.,8 J. Fung, M.D.,8; (1)Washington University School of Medicine, St Louis, MO; (2)Columbia University Medical Center, New York, NY; (3)Duke University Medical Center, Durham, NC; (4)Medical University of South Carolina, Charleston, SC; (5)University of Medicine and Dentistry – New Jersey Medical School, Newark, NJ; (6)Henry Ford Hospital, Detroit, MI; (7)Novartis AG, Basel, Switzerland; (8)Novartis Pharmaceuticals Corp., East Hanover, NJ; (9)Cleveland Clinic, Cleveland, OH

185. Efficacy and Safety of Delayed Outpatient Rabbit Anti-thymocyte Globulin Induction in De Novo African American Kidney Transplant Recipients.
Tracy M. Sparkes, Pharm.D.,1 Jennifer Trofe-Clark, Pharm.D., BCPS,2 Simin Goral, M.D.,2 Peter P. Reese, M.D., MSCE,2 Diane Jakobowski, MSN, RN,3 Stacey Doll, MPA,3 Peter L. Abt, M.D.,4 Deirdre Sawinski, M.D.,2 Roy D. Bloom, M.D.;1 (1)Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA; (2)Renal Electrolyte and Hypertension Division, Perelman
186. Incidence and Severity of Isometric Tubular Vacuolization in Renal Transplant Recipients Treated with CMV Ig or IV Ig-Glycine. 

**Andrea Passarelli, Pharm.D.,¹ Serena Bagnasco, M.D.,² Laura Lees, Pharm.D.,¹ John Lewin III, Pharm.D.,¹ Rachel Krueer, Pharm.D.,¹ Lorraine Racusen, M.D.,² Edward Kraus, M.D.,³ Kenneth Shermock, Pharm.D., Ph.D.,¹ Christopher R. Ensor, Pharm.D.D.;¹ (1)Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD; (2)Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD; (3)Department of Medicine, Division of Nephrology, The Johns Hopkins Hospital, Baltimore, MD; (4)Department of Pharmacy & Therapeutics, University of Pittsburgh, Pittsburgh, PA


**Daniel R. Stevens, Pharm.D.,¹ Jennifer Trofe-Clark, Pharm.D., BCPS,¹ Emily Blumberg, M.D.,² Marissa Wilck, M.D.,² Blair Weikert, M.D.,² Simin Goral, M.D.,³ Melissa Bleicher, M.D.,³ Deirdre Sawinski, M.D.,³ Peter L. Abt, M.D.,⁴ Matthew H. Levine, M.D., Ph.D.,⁵ Paige Porrett, M.D., Ph.D.,⁶ Nicholas Galanakis, Pharm.D. Candidate,⁷ Roy D. Bloom, M.D.;⁷ (1)Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA; (2)Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; (3)Renal Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; (4)Division of Transplant Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; (5)Department of Transplant Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; (6)Department of Transplant Surgery, Perelman School of Medicine, Philadelphia, PA; (7)University of the Sciences Philadelphia College of Pharmacy, Philadelphia, PA

188. Tacrolimus Interaction with Azole Antifungals in Kidney Transplant Recipients: Is Fluconazole or Clotrimazole a Worse Offender?

**Jane Revollo, Pharm.D.,¹ Benjamin Duhart Jr, Pharm.D., M.S.,² Alison Apple, DPh, M.S.,³ Amy Krauss, Pharm.D., BCPS;¹ (1)Pharmacy Department, Methodist University Hospital, Memphis, TN; (2)Pharmacy, University of Tennessee Health Science Center/Methodist University Hospital, Memphis, TN


**Tony K.L. Kiang, BSc(Pharm), Ph.D., ACPR,¹ Nilufar Partovi, Pharm.D.,¹ Trana Hussaini, Pharm.D.,¹ Rebecca Jean Shapiro, M.D.,² Mary H.H. Ensom, Pharm.D., FCCP, FASHP, FCSHP, FCAHS;¹ (1)Department of Pharmacy, Vancouver General Hospital, Vancouver, BC, Canada; (2)Department of Nephrology, Vancouver General Hospital, Vancouver, BC, Canada; (3)The University of British Columbia, Children’s & Women’s Health Centre of British Columbia, Vancouver, BC, Canada


**Grace Shyh, Pharm.D.,¹ Yi Guo, Pharm.D.,¹ Kwaku Marfo, Pharm.D., MPH;¹ (1)Department of Pharmacy, Montefiore Medical Center, Bronx, NY; (2)Montefiore-Einstein Center for Transplantation, Montefiore Medical Center, Bronx, NY
192E. Sex and Haplotype Associations with Adverse Effects of Calcineurin Inhibitors Post-renal Transplant.  
*Calvin Meaney, Pharm.D., BCPS,*1 Dan Brazeau, Ph.D.,2 Rocco Venuto, M.D., FASN,3 Shirley Chang, M.D.,4 Ajiaz Gundroo, M.D.,3 Nicolee Leca, M.D.,3 Sarah Morse, B.S.,4 Joseph Consiglio, M.S.,4 Louise Cooper, M.S.,4 Kathleen Tornatore, Pharm.D., FCCP1; (1)University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences; (2)University of New England College of Pharmacy; (3)University at Buffalo School of Medicine and Biomedical Sciences; (4)University at Buffalo School of Pharmacy and Pharmaceutical Sciences; (5)University at Buffalo School of Public Health

193. Long-term Blood Pressure Goal Achievement in Liver Transplant Patients Within an Underserved Community.  
*Justin Harris, Pharm.D.,1 Christina Ruggia-Check, Pharm.D., Yardlee S. Kauffman, Pharm.D., MPH,3 Thomas Delate, Ph.D., M.S.,4 David Johnson, Pharm.D.; (1)Temple University Hospital, Philadelphia, PA; (2)Pharmacy Department, Kaiser Permanente Colorado, Aurora, CO; (3)Kaiser Permanente Colorado, Aurora, CO

*Thinh Luong, N/A, Kimi Ueda, Pharm.D.; Department of Transplantation, California Pacific Medical Center, San Francisco, CA

195E. Single-Center Experience with Long-term Prospective BK Viremia Monitoring in Renal Transplantation.  
*Jennifer Trofe-Clark, Pharm.D., BCPS,*1 Deirdre Sawinski, M.D.,1 Tracy M. Sparkes, Pharm.D.,2 Simin Goral, M.D.,1 Melissa Bleicher, M.D.,1 Roy D. Bloom, M.D.;1 (1)Renal Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; (2)Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA

196F. Assessment of Rabbit Antithymocyte Globulin Dosing and Clinical Outcomes in Kidney Transplantation.  
*Heather Snyder; Pharm.D.,1 Amy Krauss, Pharm.D., BCPS,2 Vinaya Rao, M.D.,3 Dagney Ulrich, Ph.D.,4 Benjamin Duhart Jr, Pharm.D., M.S.;1 (1)Pharmacy, University of Tennessee Health Science Center/Methodist University Hospital, Memphis, TN; (2)Pharmacy Department, Methodist University Hospital, Memphis, TN; (3)Transplant Nephrology, University of Tennessee Health Science Center/Methodist University Hospital Transplant Institute, Memphis, TN; (4) Pharmacy, University of Tennessee Health Science Center, Memphis, TN

*Don Vu, Pharm.D., Ph.D.,1 Tariq Shah, M.D.,2 Ian V. Hutchinson, Ph.D., DSc,3 Robert Naraghi, M.D.,2 David I. Min, Pharm.D.; (1)National Institute of Transplantation and Western University of Health Sciences, Los Angeles, CA; (2)National Institute of Transplantation and St. Vincent Medical Center, Los Angeles, CA; (3)USC School of Pharmacy, Los Angeles, CA; (4)Western University of Health Sciences, College of Pharmacy and National Institute of Transplantation, Los Angeles, CA

*Don Vu, Pharm.D., Ph.D.,1 Robert Naraghi, M.D.,2 Ian V. Hutchinson, Ph.D., DSc,3 Tariq Shah, M.D.,2 David I. Min, Pharm.D.; (1)National Institute of Transplantation and Western University of Health Sciences, Los Angeles, CA; (2)National Institute of Transplantation and St. Vincent Medical Center, Los Angeles, CA; (3)USC School of Pharmacy, Los Angeles, CA; (4)Western University of Health Sciences, College of Pharmacy and National Institute of Transplantation, Los Angeles, CA
Don Vu, Pharm.D., Ph.D.,¹ Tariq Shah, M.D.,² Robert Naraghi, M.D.,² Jan V. Hutchinson, Ph.D., DSc,³ David I. Min, Pharm.D.⁴; (1)National Institute of Transplantation and Western University of Health Sciences, Los Angeles, CA; (2)National Institute of Transplantation and St. Vincent Medical Center, Los Angeles, CA; (3)USC School of Pharmacy, Los Angeles, CA; (4)Western University of Health Sciences, College of Pharmacy and National Institute of Transplantation, Los Angeles, CA

Women's Health

202. Rates of Post-partum Screening for Diabetes in Patients with Gestational Diabetes.  
Arezo Noormohammadi, Pharm.D., Alicia B. Forinash, Pharm.D., BCPS, BCACP, Abigail M. Yancey, Pharm.D., BCPS; St. Louis College of Pharmacy, St. Louis, MO

CLINICAL PHARMACY FORUM

These abstracts describe the delivery, development, justification, or documentation of an innovative clinical pharmacy service; they may be descriptive only and need not contain an evaluative component.

Cardiovascular

Robyn Teply, Pharm.D.,¹ Jennifer Campbell, Pharm.D.,² Mark A. Malesker, Pharm.D., FCCP, BCPS,³ Aryan Mooss, M.D.,⁴ Daniel E. Hilleman, Pharm.D., FCCP⁵; (1)Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE; (2) The Cardiac Center of Creighton University, Omaha, NE; (3)Creighton University Medical Center, Omaha, NE; (4)Creighton University Cardiac Center, Creighton University School of Medicine, Omaha, NE; (5)Creighton University Cardiac Center, Omaha, NE

220. Comparing the Impact of Two Omega-3 Fatty Acid Products on the Lipid Profile.  
Randall Sharp, Pharm.D.,¹ Lisa Appeddu, Ph.D.,² Akim Islam, M.D.,³ Riaz Sirajuddin, M.D.³; (1)College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK; (2) Southwestern Oklahoma State University, Weatherford, OK; (3)Heart Solutions of Oklahoma, Oklahoma City, OK

Clinical Administration

Seth Bauer, Pharm.D.,¹ Zachariah Thomas, Pharm.D., BCPS,² Farooq Bandali, Pharm.D.,³ Sandra L. Kane-Gill, Pharm.D., M.Sc., FCCP, FCCM,⁴ Stacy A. Voils, Pharm.D., M.S.,² Ishaq Lat, Pharm.D., FCCP, FCCM⁵; (1)Cleveland Clinic; (2)Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ; (3)Ernest Mario School of Pharmacy-Rutgers, The State University of New Jersey; (4)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (5)Virginia Commonwealth University Health System, Richmond, VA; (6)University of Chicago Medical Center

222. Dexmedetomidine High Cost Expense Reduction.  
TaMica Brown, B.S., CPhT, Sarah Adriance, Pharm.D., BCPS, Anthony Gerlach, Pharm.D., FCCM, BCPS; Pharmacy, The Ohio State University Wexner Medical Center

Charlene A. Hope, Pharm.D., BCPS; Norwegian American Hospital, Chicago, IL
Community Pharmacy Practice

224. Project ECHO: A Novel Model for Clinical Pharmacists in a Multidisciplinary Telehealth Care Network for Rural and Underserved Communities. Paulina Deming, Pharm.D.,1 Joe Anderson, Pharm.D.,1 Melanie Dodd, Pharm.D.,1 Bernadette Johnson, Pharm.D.,1 Mark Holdsworth, Pharm.D.,1 Renée-Claude Mercier, Pharm.D.,2 Gretchen Ray, Pharm.D.,1 Karla Thornton, M.D., MPH,3 Sanjeev Arora, M.D.; (1)College of Pharmacy, University of New Mexico, Albuquerque, NM; (2)University of New Mexico, Albuquerque, NM; (3)School of Medicine, University of New Mexico, Albuquerque, NM

Education/Training

226. Development of a Regional Teaching Certificate Program for Pharmacy Residents Practicing in Institutional Settings. Harminder Sikand, Pharm.D., FCSHP, FASHP; Jonathan Lacro, Pharm.D., FASHP, BCPS, BCPP; Marcie Lepkowsky, Pharm.D., Natalie Hall, Pharm.D., BCOP4 Jennigrace Bautista, Pharm.D.,5 Grant Lum, Pharm.D.,6 Gale Romanowski, Pharm.D.,7 Jennifer Floyd, Pharm.D., BCPS,8 Nahed Bahlawan, Pharm.D.,9; (1)Scripps Mercy Hospital, San Diego, CA; (2)Pharmacy, VA San Diego Healthcare System; (3)UC San Diego Health System; (4)Naval Medical Center-San Diego; (5)Kaiser Permanente; (6)Sharp Chula Vista Medical Center, Chula Vista, CA; (7)Rady Children’s; (8)Palomar Pomerado Health; (9)Naval Hospital Camp Pendleton

227. From Pilot to Practice: Feasibility & Impact of a Layered Learning Practice Model Experience in Cardiology. Bethany A. Kalich, Pharm.D., BCPS, Jonathan D. Cicci, Pharm.D., BCPS, Shailly Shah, Pharm.D., Brent N. Reed, Pharm.D., BCPS; (1)Department of Pharmacy, University of North Carolina Health Care, Chapel Hill, NC; (2)Department of Pharmacy, University of North Carolina Health Care, Chapel Hill, NC

Emergency Medicine

228. Efficacy and Safety of Intravenous N-Acetylcysteine in Obese vs. Non-obese Patients with Acetaminophen Toxicity. John J. Radosevich, Pharm.D., BCPS, Asad E. Patanwala, Pharm.D., BCPS, Brian L. Erstad, Pharm.D., FCCP, FASHP, FCCM, BCPS; The University of Arizona College of Pharmacy, Tucson, AZ

230. Medication Error Interventions in Psychiatric Patients Boarded in the Emergency Department. Hussain Baksh, Pharm.D.,1 Stephen Perona, Pharm.D.,2 Whitney Shields, Pharm.D.,2 Sara Salek, M.D.,3 Arthur Sanders, M.D.,4 Asad Patanwala, Pharm.D.; (1)The University of Arizona; (2)Pharmacy, Northwest Medical Center, Tucson, AZ; (3)Psychiatry, Veterans Affairs Palo Alto Health Care System; (4)Emergency Medicine, The University of Arizona, Tucson, AZ; (5)Pharmacy Practice and Science, The University of Arizona

231. Impact of Implementation of Clinical Pharmacy Service in the Emergency Department (ED) in a Tertiary Academic Hospital in Qatar. Hani Abdelaziz, Pharm.D., Ahmed Abdel Moneim, B(Pharm), Mohamed Abdelmoneim, B(Pharm), Ashraf El Malik, B(Pharm), Sara Fouad, B(Pharm), Mohamed Saad, B(Pharm), BCPS, Rasha Alanany, Pharm.D., Haleema Al-Tamimi, B(Pharm); Hamad General Hospital, Hamad Medical Corp., Doha, Qatar

Geriatrics

239. The Impact of a Pharmacy Resident Geriatric Clinic. Cassandra White, Pharm.D.,1 Alisa Hughes-Stricklett, Pharm.D., BCPS; (1)Pharmacy Service 119, VA Maine Healthcare System, Augusta, ME; (2)VA Maine Healthcare System, Augusta, ME
240. Clinical Characteristics and Predictors of Exacerbation in Cognitively Impaired Nursing Home Residents with Chronic Obstructive Pulmonary Disease (COPD).

Barbara Zarowitz, Pharm.D.,1 Terrence O'Shea, Pharm.D.,2 Carrie Allen, Pharm.D.; (1)Omnicare, Inc., Livonia, MI; (2)Division of Clinical Services, Omnicare, Inc., Englewood, OH; (3)West Division, Omnicare, Inc., San Antonio, TX

Infectious Diseases


Erin Scruggs, Pharm.D.,1 Neil Labak, Pharm.D.; (1)Department of Pharmacy, Carolinas Medical Center-Northeast, Concord, NC; (2)Carolinas Medical Center-Northeast, Concord, NC

244. Prospective Evaluation of Epic Antibiotic Report and SafetySurveillor to Improve Efficiency and Identification of Clinical Pharmacy Interventions.

Leanna Liu, Pharm.D.,1 Christine Hamby, Pharm.D.,1 Maura Wychowski, Pharm.D., BCPS,1 Mary Lourdes Brundige, Pharm.D.,1 Mary Butler, Pharm.D.,1 Alexandra Yamshchikov, M.D.,2 Maryrose Laguio-Vila, M.D.; (1)Department of Pharmacy, Rochester General Hospital, Rochester, NY; (2)Infectious Disease Unit, Rochester General Hospital, Rochester, NY

Other

254. A Collaborative Effort to Develop Clinical Pharmacy Services and Advanced Pharmacy Practice Experience (APPE) Student Exchange Programs in Ethiopia and China.

Golden Peters, Pharm.D., BCPS,1 Shin-Yu Lee, Pharm.D.,2 Kenneth Schafermeyer, Ph.D.; (1)St. Louis College of Pharmacy, St. Louis, MO; (2)Pharmacy Practice Division, St. Louis College of Pharmacy, St. Louis, MO; (3)Pharmacy Administration, St. Louis College of Pharmacy, St. Louis, MO


Danny McNatty, Pharm.D., MHA, BCPS, Ephu Yip, Pharm.D., Denise Erickson, Pharm.D., BCPS; Banner Health, Phoenix, AZ

256. Residency Program Implementation Through a Community-Based Research Program.

Leigh Ann Ross, Pharm.D., BCPS,1 Lauren S. Bloodworth, Pharm.D., BCPS,1 Justin J. Sherman, MCS, Pharm.D.,2 Laurie Warrington, Pharm.D., BC-ACP,1 Ashley W. Ellis, Pharm.D., BCACP,2 (1)University of Mississippi School of Pharmacy, Jackson, MS; (2)The University of Mississippi School of Pharmacy, Jackson, MS; (3)University of Mississippi, University, TN

Pharmacogenomics/Pharmacogenetics

261. Pharmacogenetically Based Use of Codeine in a Children’s Hospital Setting.

Kristine R. Creus, Pharm.D.,1 Cyrine E. Haidar, Pharm.D.,2 Gillian C. Bell, Pharm.D.,2 Ulrike M. Reiss, M.D.,2 Kelly E. Caudle, Pharm.D., Ph.D.,2 James M. Hoffman, Pharm.D., M.S., BCPS,2 Mary V. Relling, Pharm.D.; (1)Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN; (2)St. Jude Children’s Research Hospital, Memphis, TN

262. Development of a Novel PGY2 Pharmacogenomics and Drug Information Residency in a Personalized Medicine Program.

Aniwa Owusu Obeng, Pharm.D.,1 Kristin Weitzel, Pharm.D., FAPhA, CDE, Julie Johnson, Pharm.D., FCCP, FAHA, BCPS; (1)UF Health Personalized Medicine Program; Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida, Gainesville, FL; (2)UF Health Personalized Medicine Program; Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics; University of Florida, Gainesville, FL
Psychiatry

264. Impact of Pharmacist Educational Inservice on Psychotropic Medication Polypharmacy at a State-Supported Living Center.
Abimbola Farinde, Pharm.D., M.S., BCPP, CGP; Clear Lake Regional Medical Center, Webster, TX

Substance Abuse/Toxicology

266. Clinical Pharmacy Services: Interpreting Toxicology Laboratory Results.
Anne DePriest, Pharm.D., BCPS, Julie Knight, Pharm.D., Brandi Puet, Pharm.D., Katie Miller, Pharm.D., David Black, Ph.D., D-ABFT; Aegis Sciences Corp., Nashville, TN

Transplantation/Immunology

Mike Latran, Pharm.D., Michael Duncan, M.D., Chadi Hage, M.D., David Roe, M.D.; (1)Pharmacy, IU Health Methodist Hospital, Indianapolis, IN; (2)IU Health Methodist Hospital

Women’s Health

268. Development and Review of an Interprofessional Bone Health Program.
Sarah M. Westberg, Pharm.D., BCPS, Sharon S. Allen, M.D., Ph.D., Erin Kraemer, Pharm.D.; (1)University of Minnesota College of Pharmacy, Minneapolis, MN; (2)University of Minnesota School of Medicine, Family Medicine and Community Health, Minneapolis, MN; (3)University of Minnesota College of Pharmacy

ORIGINAL RESEARCH

Cardiology

394. Retrospective analysis of QT interval monitoring in hospitalized patients prescribed antipsychotics
Deidra Dickerson, Pharm.D., Jennifer Twilla, Pharm.D., BCPS, Lydia Hutchison, Pharm.D., BCPS, CGP, Ana Negrete, Pharm.D., BCPS and Carrie S. Oliphant, Pharm.D, BCPS, (AQ, Cardiology) Methodist University Hospital, Memphis, TN